Key result
The sodium-restricted DASH diet reduced clinic systolic blood pressure from 155 to 138 mm Hg (P=0.02) and improved arterial stiffness and oxidative stress in patients with hypertensive HFPEF.
Why the study?
Does the sodium-restricted Dietary Approaches to Stop Hypertension diet (DASH/SRD) reduce blood pressure, arterial stiffness, and oxidative stress in patients with treated hypertension and compensated HFPEF?
Does the sodium-restricted Dietary Approaches to Stop Hypertension diet (DASH/SRD) reduce blood pressure, arterial stiffness, and oxidative stress in patients with treated hypertension and compensated HFPEF?
A sodium-restricted DASH diet significantly reduces systemic blood pressure, arterial stiffness, and oxidative stress in patients with hypertensive HFpEF over 21 days.
Answers are grounded in this paper and cite their sources.
Does not support practice change in hypertensive HFpEF; leaves open need for RCTs on outcomes.
Recent studies suggest that oxidative stress and vascular dysfunction contribute to heart failure with preserved ejection fraction (HFPEF). In salt-sensitive HFPEF animal models, diets low in sodium and high in potassium, calcium, magnesium, and antioxidants attenuate oxidative stress and cardiovascular damage. We hypothesized that the sodium-restricted Dietary Approaches to Stop Hypertension diet (DASH/SRD) would have similar effects in human hypertensive HFPEF. Thirteen patients with treated hypertension and compensated HFPEF consumed the DASH/SRD for 21 days (all food/most beverages provided). The DASH/SRD reduced clinic systolic (155-138 mm Hg; P=0.02) and diastolic blood pressure (79-72 mm Hg; P=0.04), 24-hour ambulatory systolic (130-123 mm Hg; P=0.02) and diastolic blood pressure (67-62 mm Hg; P=0.02), and carotid-femoral pulse wave velocity (12.4-11.0 m/s; P=0.03). Urinary F2-isoprostanes decreased by 31% (209-144 pmol/mmol Cr; P=0.02) despite increased urinary aldosterone excretion. The reduction in urinary F2-isoprostanes closely correlated with the reduction in urinary sodium excretion on the DASH/SRD. In this cohort of HFPEF patients with treated hypertension, the DASH/SRD reduced systemic blood pressure, arterial stiffness, and oxidative stress. These findings are characteristic of salt-sensitive hypertension, a phenotype present in many HFPEF animal models and suggest shared pathophysiological mechanisms linking these 2 conditions. Further dietary modification studies could provide insights into the development and progression of hypertensive HFPEF.
No takes yet. Share an insight, caveat, or question.
Hummel et al. (2012) studied Hypertensive heart failure with preserved ejection fraction (HFPEF) (n=13). Sodium-restricted Dietary Approaches to Stop Hypertension diet (DASH/SRD) vs. Baseline was evaluated on Clinic systolic blood pressure (p=0.02). The sodium-restricted DASH diet reduced clinic systolic blood pressure from 155 to 138 mm Hg (P=0.02) and improved arterial stiffness and oxidative stress in patients with hypertensive HFPEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: